Phase III Clinical Trial of FXS6837 Capsules for Paroxysmal Nocturnal Hemoglobinuria Initiated in China by Fosun Pharma

Stock News11-04 17:52

Fosun Pharma (02196) has issued an announcement that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has launched a Phase III clinical trial in China for FXS6837 capsules (formerly known as project code XH-S003) for the treatment of paroxysmal nocturnal hemoglobinuria.

The announcement was released by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196), the listed entity FOSUN PHARMA, confirming that Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196) is the parent group company involved in this development. The trial marks a significant step in the clinical development of FXS6837 for this rare blood disorder.

The Phase III trial is the final stage of clinical testing before a drug can be submitted for regulatory approval, and its initiation indicates that FXS6837 has advanced through earlier phases of safety and efficacy evaluation. Paroxysmal nocturnal hemoglobinuria is a rare, acquired, life-threatening blood disease characterized by the destruction of red blood cells, blood clots, and bone marrow failure.

The controlling subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is responsible for the clinical development of FXS6837. The trial's commencement in China represents progress in the company's pipeline for hematology treatments. Further details regarding the trial design, endpoints, or timelines were not disclosed in the announcement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179429142?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-04 17:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179429142","market":"hk","top_or_hot":-1,"title":"Phase III Clinical Trial of FXS6837 Capsules for Paroxysmal Nocturnal Hemoglobinuria Initiated in China by Fosun Pharma","media":"Stock News","content":"<p>Fosun Pharma (02196) has issued an announcement that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has launched a Phase III clinical trial in China for FXS6837 capsules (formerly known as project code XH-S003) for the treatment of paroxysmal nocturnal hemoglobinuria.<br><br>The announcement was released by <b>Shanghai Fosun Pharmaceutical (Group) Co., Ltd.</b> (<b>02196</b>), the listed entity <b>FOSUN PHARMA</b>, confirming that <b>Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.</b> (<b>600196</b>) is the parent group company involved in this development. The trial marks a significant step in the clinical development of FXS6837 for this rare blood disorder.<br><br>The Phase III trial is the final stage of clinical testing before a drug can be submitted for regulatory approval, and its initiation indicates that FXS6837 has advanced through earlier phases of safety and efficacy evaluation. Paroxysmal nocturnal hemoglobinuria is a rare, acquired, life-threatening blood disease characterized by the destruction of red blood cells, blood clots, and bone marrow failure.<br><br>The controlling subsidiary, <b>Shanghai Fosun Pharmaceutical Industry Development Co., Ltd.</b>, is responsible for the clinical development of FXS6837. The trial's commencement in China represents progress in the company's pipeline for hematology treatments. Further details regarding the trial design, endpoints, or timelines were not disclosed in the announcement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Phase III Clinical Trial of FXS6837 Capsules for Paroxysmal Nocturnal Hemoglobinuria Initiated in China by Fosun Pharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhase III Clinical Trial of FXS6837 Capsules for Paroxysmal Nocturnal Hemoglobinuria Initiated in China by Fosun Pharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-11-04 17:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fosun Pharma (02196) has issued an announcement that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has launched a Phase III clinical trial in China for FXS6837 capsules (formerly known as project code XH-S003) for the treatment of paroxysmal nocturnal hemoglobinuria.<br><br>The announcement was released by <b>Shanghai Fosun Pharmaceutical (Group) Co., Ltd.</b> (<b>02196</b>), the listed entity <b>FOSUN PHARMA</b>, confirming that <b>Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.</b> (<b>600196</b>) is the parent group company involved in this development. The trial marks a significant step in the clinical development of FXS6837 for this rare blood disorder.<br><br>The Phase III trial is the final stage of clinical testing before a drug can be submitted for regulatory approval, and its initiation indicates that FXS6837 has advanced through earlier phases of safety and efficacy evaluation. Paroxysmal nocturnal hemoglobinuria is a rare, acquired, life-threatening blood disease characterized by the destruction of red blood cells, blood clots, and bone marrow failure.<br><br>The controlling subsidiary, <b>Shanghai Fosun Pharmaceutical Industry Development Co., Ltd.</b>, is responsible for the clinical development of FXS6837. The trial's commencement in China represents progress in the company's pipeline for hematology treatments. Further details regarding the trial design, endpoints, or timelines were not disclosed in the announcement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0096","symbol_name":"民营医院","start_time":0,"source_url":"","article_id":"1179429142","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179429142","pubTimestamp":1793785936,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Fosun Pharma (02196) has issued an announcement that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has launched a Phase III clinical trial in China for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0096":"民营医院","BK0183":"MSCI概念","BK0188":"融资融券","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0012":"证金概念","BK0187":"一线龙头","BK0028":"国家队","BK1191":"制药","BK1593":"医美概念股","MDTX":"Corgi MediaTek 2x Daily ETF","BK0175":"白马股","BK0060":"抗癌","BMED":"iShares Health Innovation Active ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","PSYK":"PSYK ETF","02196":"复星医药","BK1515":"抗疫概念","BK0196":"行业龙头","BK0239":"医药制造"},"translate_title":"复星医药在中国启动FXS6837胶囊治疗阵发性睡眠性血红蛋白尿的III期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1,"IBBQ":1,"BMED":1,"MDTX":1,"IBBJ":1,"PSYK":1},"content_text":"Fosun Pharma (02196) has issued an announcement that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has launched a Phase III clinical trial in China for FXS6837 capsules (formerly known as project code XH-S003) for the treatment of paroxysmal nocturnal hemoglobinuria.The announcement was released by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196), the listed entity FOSUN PHARMA, confirming that Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196) is the parent group company involved in this development. The trial marks a significant step in the clinical development of FXS6837 for this rare blood disorder.The Phase III trial is the final stage of clinical testing before a drug can be submitted for regulatory approval, and its initiation indicates that FXS6837 has advanced through earlier phases of safety and efficacy evaluation. Paroxysmal nocturnal hemoglobinuria is a rare, acquired, life-threatening blood disease characterized by the destruction of red blood cells, blood clots, and bone marrow failure.The controlling subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is responsible for the clinical development of FXS6837. The trial's commencement in China represents progress in the company's pipeline for hematology treatments. Further details regarding the trial design, endpoints, or timelines were not disclosed in the announcement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179429142","isCrawlerRequest":true}